Mobile health technology supported rehabilitation for patients with atrial fibrillation

Structured rehabilitation for patients with atrial fibrillation based on an integrated care approach: a prospective, observational cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13724416

Enrollment

1039

Registered

2022-06-15

Start date

2021-05-01

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Circulatory System Atrial fibrillation and flutter

Interventions

In this prospective, observational cohort study, patients with atrial fibrillation aged =18 years will be enrolled using the mobile Atrial Fibrillation Application III for self-management. Assuming an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged =18 years old 2. Patients had >30-s AF on a 12-lead resting electrocardiogram or Holter 3. Patient informed consent form is signed

Exclusion criteria

Exclusion criteria: 1. No ECG of AF is recorded 2. No informed consent is provided

Design outcomes

Primary

Measure	Time frame
Adherence to guidelines based on the ABC pathway and its individual components, measured with questionnaire or telephone or clinic visit at 1 year	—

Secondary

Measure	Time frame
Measured with questionnaire or telephone or clinic visit at 1 year: 1. The composite of stroke/thromboembolism, all-cause death and rehospitalization: 1.1. The thromboembolism endpoint includes ischaemic stroke, transient ischaemic attack (TIA), pulmonary embolism, deep vein thromboembolism (DVT), and other thromboembolisms (e.g., peripheral embolism, atrial thrombus and left atrial appendage thrombus) 1.2. All-cause death will include cardiac death, vascular death and non-cardiovascular death 1.3. Cardiac death includes death caused by ST-segment elevation myocardial infarction/non-ST-segment elevation myocardial infarction (STEMI/NSTEMI), heart failure (HF), arrhythmia, cardiac perforation/tamponade and other deaths of cardiac origin 1.4. Vascular death will include death ascribed to ischaemic stroke, haemorrhagic stroke, systemic haemorrhage, peripheral embolism and pulmonary embolism 1.5. Rehospitalization for cardiovascular events will include stroke, systemic thromboembolism, angina, STEMI/NSTEMI, HF, and arrhythmia 2. AF recurrence after 3 months following AF ablation 3. Compliance with guideline-recommended antithrombotic management for patients undergoing LAAO or ablation plus LAAO 4. Event rates: event rate for the composite of ischaemic stroke/TIA and systemic thromboembolism, HF, cardiovascular death or rehospitalization for any cardiac cause 5. Quality of life	—

Measure

Time frame

Measured with questionnaire or telephone or clinic visit at 1 year: 1. The composite of stroke/thromboembolism, all-cause death and rehospitalization: 1.1. The thromboembolism endpoint includes ischaemic stroke, transient ischaemic attack (TIA), pulmonary embolism, deep vein thromboembolism (DVT), and other thromboembolisms (e.g., peripheral embolism, atrial thrombus and left atrial appendage thrombus) 1.2. All-cause death will include cardiac death, vascular death and non-cardiovascular death 1.3. Cardiac death includes death caused by ST-segment elevation myocardial infarction/non-ST-segment elevation myocardial infarction (STEMI/NSTEMI), heart failure (HF), arrhythmia, cardiac perforation/tamponade and other deaths of cardiac origin 1.4. Vascular death will include death ascribed to ischaemic stroke, haemorrhagic stroke, systemic haemorrhage, peripheral embolism and pulmonary embolism 1.5. Rehospitalization for cardiovascular events will include stroke, systemic thromboembolism, angina, STEMI/NSTEMI, HF, and arrhythmia 2. AF recurrence after 3 months following AF ablation 3. Compliance with guideline-recommended antithrombotic management for patients undergoing LAAO or ablation plus LAAO 4. Event rates: event rate for the composite of ischaemic stroke/TIA and systemic thromboembolism, HF, cardiovascular death or rehospitalization for any cardiac cause 5. Quality of life

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 9, 2026